反应详情

A solution of (±)-tert-butyl 4-((1-(5-chloro-3-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate (406 mg, 0.632 mmol) and TBAF (4 mL, 4.00 mmol) (1M in THF) in THF (10 mL) was heated at reflux for 8 hours then cooled to ambient temperature and the solvent was evaporated. Purified on SiO2 column with 50% ethyl acetate/hexanes to obtain (±)-tert-butyl 4-((1-(5-chloro-3-cyano-1H-indol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate (231 mg, 0.451 mmol, 71.4% yield) as a clear foam. 1H-NMR (CDCl3, 400 MHz) δ 8.11 (bs, 1H), 7.57 (d, J=1.9 Hz, 1H), 7.27 (m, 2H), 7.11 (m, 2H), 7.10 (s, 1H), 4.54 (q, J=6.5 Hz, 1H), 3.7 (m, 2H), 3.43(d, J=8.8 Hz, 1H), 3.20 (d, J=8.6 Hz, 1H), 3.10 (t, J=7.5 Hz, 1H), 2.97 (t, J=10.1 Hz, 1H), 2.38 (m, 2H), 1.80-2.00 (m, 2H), 1.64 (m, 1H), 1.40 (s, 3H). LC/MS (HPLC method 4): tR=4.02 min, 534.13(MNa)+.

1. temperatureat reflux for 8 hours
2. customthe solvent was evaporated
3. customPurified on SiO2 column with 50% ethyl acetate/hexanes